Skip to main content

Table 1 Study characteristic

From: Associating the risk of three urinary cancers with obesity and overweight: an overview with evidence mapping of systematic reviews

Study Year Compliance of AMSTAR/overall confidence PRISMA scores Cancer Study design Effect size No. of studies
Qin [22] 2013 9/critically low 21 Bladder cancer Cohort RR 11
Sun [23] 2015 9/critically low 21 Bladder cancer Cohort RR 15
Zhao [24] 2017 13/critically low 23 Bladder cancer Cohort RR 14
Bagheri [25] 2016 7/critically low 17.5 Kidney cancer Cohort HR 8
Bergström [26] 2001 4/critically low 15.5 Kidney cancer Cohort, case-control RR 29
Ildaphonse [27] 2009 3/critically low 12.5 Kidney cancer Cohort OR, RR 27
Mathew [28] 2009 4/critically low 13 Kidney cancer Cohort OR, RR 28
Wang [29] 2014 7/critically low 23 Kidney cancer Cohort RR 21
Zhang [30] 2018 10/critically low 21.5 Kidney cancer Cohort HR 19
Chen [31] 2016 9/critically low 22.5 Prostate cancer Cohort, case-control RR 9
Discacciati [32] 2012 9/critically low 19.5 Prostate cancer Cohort RR 12
Jiang [33] 2017 12/critically low 19.5 Prostate cancer Cohort RR 9
MacInnis [34] 2006 6/critically low 24 Prostate cancer Cohort RR 56
Xie [35] 2017 10/critically low 20.5 Prostate cancer Cohort RR 21
Zhang [36] 2015 9/critically low 18.5 Prostate cancer Cohort, case-control RR 17
Zhong [37] 2016 8/critically low 24.5 Prostate cancer Cohort, case-control RR 24
Guh [38] 2009 8/critically low 18.5 Prostate cancer
Kidney cancer
Cohort RR 13
Fang [39] 2018 11/critically low 23 Prostate cancer
Kidney cancer
Bladder cancer
Cohort RR 87
Al-Zalabani [40] 2016 10/critically low 25.5 Bladder cancer Cohort RR 26
Wang [41] 2016 9/critically low 24.5 Prostate cancer
Kidney cancer
Cohort RR 59
Robinson [42] 2008 7/critically low 21.5 Prostate cancer Cohort, case-control RR 16
Renehan [43] 2008 12/critically low 25 Prostate cancer
Kidney cancer
Cohort, case-control RR 44
Bergstom [44] 2001 4/critically low 14.5 Prostate cancer
Kidney cancer
Cohort, case-control RR 17
Cao [45] 2011 9/critically low 19 Prostate cancer Cohort RR 8
Xue [46] 2017 11/critically low 23.5 Kidney cancer
Bladder cancer
Cohort RR 24
Wang [47] 2008 8/critically low 24 Kidney cancer Cohort, case-control RR 44
Dobbins [48] 2013 7/critically low 20.5 Prostate cancer Cohort, case-control RR 5
Liu [49] 2018 9/critically low 23.5 Kidney cancer Cohort RR 24
Hidayat [50] 2018 9/critically low 22 Kidney cancer
Prostate cancer
Cohort, case-control RR 18
Harrison et al. [51] 2020 12/critically low 25 Prostate cancer Cohort, case-control OR 21
Berger et al. [52] 2019 12/critically low 26 Prostate cancer Cohort RR 12